SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2013
Prana Biotechnology Limited
(Name of Registrant)
Level 2, 369 Royal Parade Parkville Victoria 3052 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):______
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):______
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____
PRANA BIOTECHNOLOGY LIMITED
6-K Items
1. Appendix 4C
Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments
Rule 4.7B
Appendix 4C – 4th Quarter
Quarterly report
for entities admitted
on the basis of commitments
Introduced 31/3/2000. Amended 30/9/2001
| Name of Entity: |
| PRANA BIOTECHNOLOGY LIMITED |
| ABN: | Quarter Ended ('Current Quarter') | |
| 37 080 699 065 | 30th June, 2013 |
Consolidated Statement of Cash Flows
|
Cash Flows Related to Operating Activities |
Current Quarter $A’000 |
Year to Date (12 months) $A’000 | |
| 1.1 | Receipts from customers | - | - |
| 1.2 |
Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital |
(341) (30) (2,333) - (285) |
(1,340) (124) (7,735) - (1,504) |
| 1.3 | Dividends received | - | - |
| 1.4 | Interest and other items of a similar nature received | 34 | 93 |
| 1.5 | Interest and other costs of finance paid | - | - |
| 1.6 | Income taxes paid | - | - |
| 1.7 | Other (Grants/Donations) | - | 2,552 |
| Net Operating Cash Flows | (2,955) | (8,058) | |
Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments
|
Current Quarter $A’000 |
Year to Date (12 months) $A’000 | ||
| 1.8 | Net Operating Cash Flows (carried forward) | (2,955) | (8,058) |
|
Cash Flows Related to Investing Activities |
|||
| 1.9 |
Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets |
- - - (11) - |
- - - (21) (6) |
| 1.10 |
Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets |
- - - - - |
- - - - - |
| 1.11 | Loans to other entities | - | - |
| 1.12 | Loans repaid by other entities | - | - |
| 1.13 | Other | - | - |
|
Net Investing Cash Flows |
(11) | (27) | |
| 1.14 | Total Operating and Investing Cash Flows | (2,966) | (8,085) |
|
Cash Flows Related to Financing Activities |
|||
| 1.15 | Proceeds from issues of shares, options, etc. | 7,321 | 16,142 |
| 1.16 | Proceeds from sale of forfeited shares | - | - |
| 1.17 | Proceeds from borrowings | - | 337 |
| 1.18 | Repayment of borrowings | - | - |
| 1.19 | Dividends paid | - | - |
| 1.20 | Other (Capital Raising Costs) | (506) | (943) |
| Net Financing Cash Flows | 6,815 | 15,536 | |
|
Net Increase / (Decrease) in Cash Held
|
3,849 | 7,451 | |
| 1.21 | Cash at beginning of quarter/year to date | 9,137 | 5,637 |
| 1.22 | Exchange rate adjustments to item 1.21 | 361 | 259 |
| 1.23 | Cash at End of Quarter | 13,347 | 13,347 |
Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments
Payments to Directors of the Entity and Associates of the Directors
Payments to Related Entities of the Entity and Associates of the Related Entities
|
|
Current Quarter $A'000 | |
|
1.24 |
Aggregate amount of payments to the parties included in item 1.2
|
135 |
|
1.25 |
Aggregate amount of loans to the parties included in item 1.11
|
|
|
1.26 |
Explanation necessary for an understanding of the transactions | |
|
|
Salaries, directors’ fees and consulting fees at normal commercial rates.
| |
Non-Cash Financing and Investing Activities
| 2.1 | Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows |
|
During the period, in accordance with the Employee Incentive Scheme and Consulting Agreements, 1,683,791 unlisted options were issued to employees and consultants.
|
| 2.2 | Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest |
|
-
|
Financing Facilities Available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
|
Amount Available $A’000 |
Amount Used $A’000 | ||
| 3.1 |
Loan facilities
|
- | - |
| 3.2 |
Credit standby arrangements
|
- | - |
Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments
Reconciliation of Cash
|
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. |
Current Quarter $A’000 |
Previous Quarter $A’000 | |
| 4.1 | Cash on hand and at bank | 13,347 | 9,137 |
| 4.2 | Deposits at call | - | - |
| 4.3 | Bank overdraft | - | - |
| 4.4 | Other (provide details) | - | - |
| Total: Cash at End of Quarter (item 1.22) | 13,347 | 9,137 | |
Acquisitions and Disposals of Business Entities
|
Acquisitions (Item 1.9(a)) |
Disposals (Item 1.10(a)) | ||
| 5.1 | Name of entity | - | - |
| 5.2 | Place of incorporation or registration | - | - |
| 5.3 |
Consideration for acquisition or disposal |
- | - |
| 5.4 | Total net assets | - | - |
| 5.5 | Nature of business |
-
|
-
|
Compliance Statement
| 1 | This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX. |
| 2 | This statement does give a true and fair view of the matters disclosed. |
Sign Here: Date: 31st July 2013
Company Secretary
Print Name: Richard Revelins
The CFO Solution
31.07.2013
Appendix 4C
Quarterly Report for Entities
Admitted on the Basis of Commitments
Notes
| 1. | The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report. |
| 2. | The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below. |
| · 6.2 | - reconciliation of cash flows arising from operating activities to operating profit or loss |
| · 9.2 | - itemised disclosure relating to acquisitions |
| · 9.4 | - itemised disclosure relating to disposals |
| · 12.1(a) | - policy for classification of cash items |
| · 12.3 | - disclosure of restrictions on use of cash |
| · 13.1 | - comparative information |
| 3. | Accounting Standards. ASX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PRANA BIOTECHNOLOGY LIMITED | ||
| (Registrant) | ||
| By: | /s/ Geoffrey Kempler | |
| Geoffrey
Kempler, Executive Chairman | ||
August 1, 2013